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Several aldo–keto reductase (AKR) enzymes from subfamilies 1B and 1C show retinalde-
hyde reductase activity, having low Km and kcat values. Only AKR1B10 and 1B12, with
all-trans-retinaldehyde, and AKR1C3, with 9-cis-retinaldehyde, display high catalytic efﬁ-
ciency. Major structural determinants for retinaldehyde isomer speciﬁcity are located in
the external loops (A and C for AKR1B10, and B for AKR1C3), as assessed by site-directed
mutagenesis and molecular dynamics. Cellular models have shown that AKR1B and 1C
enzymes arewell suited towork in vivo as retinaldehyde reductases and to regulate retinoic
acid (RA) biosynthesis at hormone pre-receptor level. An additional physiological role for
the retinaldehyde reductase activity of these enzymes, consistent with their tissue local-
ization, is their participation in β-carotene absorption. Retinaldehyde metabolism may be
subjected to subcellular compartmentalization, based on enzyme localization. While reti-
naldehyde oxidation to RA takes place in the cytosol, reduction to retinol could take place
in the cytosol by AKRs or in the membranes of endoplasmic reticulum by microsomal reti-
naldehyde reductases. Upregulation of some AKR1 enzymes in different cancer types may
be linked to their induction by oxidative stress and to their participation in different signaling
pathways related to cell proliferation. AKR1B10 and AKR1C3, through their retinaldehyde
reductase activity, trigger a decrease in the RA biosynthesis ﬂow, resulting in RA depriva-
tion and consequently lower differentiation, with an increased cancer risk in target tissues.
Rational design of selective AKR inhibitors could lead to development of novel drugs for
cancer treatment as well as reduction of chemotherapeutic drug resistance.
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INTRODUCTION
Members of the aldo–keto reductase (AKR) superfamily are
NADP(H)-dependent cytosolic enzymes which fold into a typical
(α/β)8-barrel. AKRs catalyze the reduction of a wide variety of car-
bonyl compounds (Jez et al., 1997; Barski et al., 2008).With regard
to the biological function of human AKRs, they may be involved
in the detoxiﬁcation of electrophilic compounds, such as 4-
hydroxy-trans-2-nonenal generated under oxidative stress condi-
tions.AKRs are also able to reduce a variety of lipophilic substrates,
such as ketosteroids, ketoprostaglandins, and retinoids, which are
hormone precursors. Thus, another function may be related to
pre-receptor hormone regulation of the amount of ligand avail-
able for some nuclear receptors and, therefore, to participation in
transcriptional gene control. Lastly, they are considered as phase I
drug-metabolizing enzymes and can either detoxify or activate
Abbreviations: ADH, alcohol dehydrogenase; AKR, aldo–keto reductase; ALDH,
aldehyde dehydrogenase; BCO1, β-carotene 15,15′-monooxygenase 1; CRABP, cel-
lular retinoic acid binding protein; CRBP-I, -II, cellular retinol binding protein type
I, II; CYP26, cytochrome P450 family 26; LRAT, lecithin:retinol acyl transferase;
MD, molecular dynamics; MDR, medium-chain dehydrogenase/reductase; PPARγ,
peroxisome proliferator-activated receptor γ; RA, retinoic acid; RALDH, retinalde-
hyde dehydrogenase; RAR, retinoic acid receptor; RBP, retinol binding protein; REH,
retinyl ester hydrolase; ROS, reactive oxygen species; RXR, retinoid X receptor; SDR,
short-chain dehydrogenase/reductase; STRA6, stimulated by retinoic acid gene 6;
TTR, transthyretin.
xenobiotic compounds (i.e., polycyclic aromatic hydrocarbons;
Penning and Drury, 2007).
With respect to the human AKRs, members of the AKR1B
subfamily are of special interest. AKR1B1, the classical aldose
reductase, is related to secondary diabetic complications, while
AKR1B10 is induced in cancer cells. Although these two AKRs
share 71% sequence identity, they show very different kinetic
properties with some relevant substrates like retinaldehyde or glu-
cose. Thus, AKR1B10 is a retinaldehyde reductase with a much
higher kcat value than that of AKR1B1, while glucose is reduced by
AKR1B1 but not by AKR1B10. Recently, AKR1B10 has emerged
as a tumor marker since it is overexpressed in different types of
cancers, featuring hepatocellular carcinoma and lung cancer cor-
related with tobacco smoking (Ruiz et al., 2009; Wang et al., 2009;
Díez-Dacal et al., 2011).
AKR1C1–AKR1C4, also known as human hydroxysteroid
dehydrogenases, share 86% sequence identity, but the individual
enzymes show different substrate speciﬁcity, inhibitor selectiv-
ity, and tissue expression pattern. AKR1C3 is one of the most
interesting enzymes, with increasing evidence strongly supporting
its involvement in cancer development (Jin and Penning, 2007;
Penning and Byrns, 2009; Ruiz et al., 2011b).
The term “retinoid” refers to compounds derived from vita-
min A (retinol), where their basic structure is divided into three
domains: a cyclohexene ring or β-ionone, an aliphatic chain with
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four conjugated double bonds, and a polar group which may show
different oxidation states. The different conﬁguration of these
double bonds leads to different stereoisomers, being the most fre-
quent all-trans, 9-cis, 11-cis, and 13-cis (Blomhoff and Blomhoff,
2006). Retinol and its derivatives retinaldehyde and retinoic acid
(RA) are essential for the growth and maintenance of many body
tissues, such as skin, bone, and vasculature, as well as for the visual
cycle (11-cis-retinaldehyde) and immune function. They also play
a role in reproduction, embryonic growth, and development. In
this sense, RA is a key molecule in the development of different
vertebrate organs and tissues by promoting cell differentiation and
apoptosis. RA has also a role in several pathological conditions,
such as skin diseases, premature birth, and rheumatoid arthritis.
Various human cancers have altered retinoid metabolism and low
RA levels,which favor tumor progression (Theodosiou et al., 2010;
Tang and Gudas, 2011).
Vitamin A incorporation in the body occurs through dietary
intake of animal products, which are a source of retinyl esters,
and from the consumption of fruits and vegetables, which are
a source of carotenoids, mainly β-carotene (Figure 1A). In the
ﬁrst case, retinol is absorbed by the enterocyte cell after retinyl
esters have been hydrolyzed in the small intestine. In the second
case, β-carotene is absorbed directly by passive diffusion, and then
in the enterocyte is split into two retinaldehyde molecules due
FIGURE 1 | Schematic diagram of retinoid absorption, transport, and
metabolism. (A) Upon dietary intake and intestinal absorption, retinoids,
and carotenoids are converted to retinol, which is bound to CRBP-II.
Retinol is further processed to retinyl esters, incorporated into
chylomicrons, and transported to the liver. In hepatocytes, retinyl esters
are hydrolyzed to retinol which forms a complex with CRBP-I. Retinol can
then be transferred to stellate cells for storage as retinyl esters.
Alternatively, retinol may bind to RBP, and the retinol:RBP complex is
bound toTTR and transferred to circulation for transport to target tissues.
Binding to TTR reduces renal clearance. Adapted with permission from
(Theodosiou et al., 2010). Copyright©2010, Birkhäuser Verlag, Basel. (B) In
the target tissues, STRA6, a cell-surface receptor for RBP, facilitates retinol
entry. Carotenoids may be also a major source of cellular retinoids. Levels
of CRBP-I, LRAT, REH, and oxidoreductases (ADH, SDR, AKR, and RALDH)
inﬂuence the retinoid ﬂow either toward the storage pathway or the
synthesis of RA, which is bound to CRABP. RA enters the nucleus, where
it binds to nuclear receptors. RA is degraded and eliminated by CYP26
enzymes. Adapted with permission from (Parés et al., 2008).
Copyright©2008, Birkhäuser Verlag, Basel. ADH, alcohol dehydrogenase;
AKR, aldo–keto reductase; BCO1, β-carotene 15,15′-monooxygenase 1;
CRABP, cellular retinoic acid binding protein; CRBP-I, -II, cellular retinol
binding protein type I, -II; CYP26, cytochrome P450 family 26; LRAT,
lecithin:retinol acetyltransferase; RA, retinoic acid; RALDH, retinaldehyde
dehydrogenase; RBP, retinol binding protein; REH, retinyl ester hydrolase;
SDR, short-chain dehydrogenase/reductase; STRA6, stimulated by retinoic
acid gene 6; TTR, transthyretin.
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to the activity of β-carotene 15,15′-monooxygenase 1 (BCO1).
The liver is another tissue which contributes signiﬁcantly to β-
carotene cleavage. Later, retinaldehyde is reduced to retinol. In the
cell, retinol has two metabolic alternatives: storage or oxidative
metabolism. One form of storage is through binding to cellu-
lar retinol binding protein type I and type II (CRBP-I and II,
respectively). CRBP-I shows wide tissue expression, while CRBP-
II is expressed in the small intestine. In the enterocyte, retinol is
attached toCRBP-II, and through the action of lecithin:retinol acyl
transferase (LRAT) is esteriﬁed with fatty acids to yield long-chain
esters of retinol. These are packaged into chylomicrons and are
transported to the liver parenchymal cells where they are captured
by speciﬁc receptors and transferred to stellate cells for storage,
which constitutes 50–80% of body retinol in the form of retinyl
esters. When required in the peripheral tissues, retinyl esters are
hydrolyzed to retinol by retinol ester hydrolase (REH). The retinol
generated is secreted and transported in the blood as a complex
between retinol and the plasmatic retinol binding protein (RBP),
which in turn is complexed with transthyretin (TTR) to reduce its
glomerular ﬁltration. Over 90% of retinol entering the cell is recy-
cled to the plasma, and only a small part is esteriﬁed for storage,
activated to RA or catabolized (Theodosiou et al., 2010; Harrison,
2012; Shirakami et al., 2012).
Biosynthesis of RA, the most potent biologically active metabo-
lite of vitamin A, requires two oxidative steps (Figure 1B). Mem-
bers of three oxidoreductase superfamilies have been implicated
in the reversible oxidation of retinol to retinaldehyde, which is the
pathway rate-limiting step (Napoli, 1999; Belyaeva et al., 2008).
The participation of cytosolic alcohol dehydrogenases (ADH)
from the medium-chain dehydrogenase/reductase (MDR) super-
family and of microsomal short-chain dehydrogenases/reductases
(SDR) has been deeply studied. More recently, the AKR super-
family has been added as a novel group of cytosolic enzymes that
could contribute to retinoid redox conversions. Basedon the cofac-
tor speciﬁcity, ADH (NAD-dependent) may work in the oxidative
direction, AKRs (NADPH-dependent) in the reductive direction,
while SDR show examples of both speciﬁcities.
The control of retinaldehyde levels is essential in the regula-
tion of RA synthesis and, therefore, of its signaling role. Once
retinaldehyde is synthesized, it has two alternative metabolic fates,
its irreversible oxidation to RA by the action of aldehyde dehy-
drogenases (ALDH or RALDH) or its reduction back to retinol
by retinaldehyde reductases. Synthesized RA binds to cellular RA
binding protein (CRABP) and is transported to the cell nucleus
where it binds to retinoid receptors. These can be divided into two
subgroups: RA receptors (RAR), binding the isomers all-trans and
9-cis-RA, and retinoid X receptors (RXR), binding 9-cis-RA with
high afﬁnity, but not all-trans-RA. RAR/RXR heterodimers are
bound to RA response elements (RARE) in DNA. Ligand binding
induces a conformational change in the RAR/RXR heterodimers
which promotes gene transcription. While RAR only forms het-
erodimers with RXR receptor (RAR–RXR), RXR is capable also to
form heterodimers with thyroid hormone (RXR–TR), vitamin D
(RXR–DR), and peroxisomal proliferator-activated (RXR–PPAR)
receptors. It appears that the RXR activity is subordinated to the
presence of ligand bound to RAR in the heterodimer (Pogenberg
et al., 2005). There is a balance between synthesis and catabolism
to control RA levels. RA catabolism to more oxidized metabo-
lites such as 4-hydroxy-RA or 4-oxo-RA occurs primarily through
enzymes from the CYP26 family (Parés et al., 2008; Theodosiou
et al., 2010; Tang and Gudas, 2011; Kumar et al., 2012).
TheﬁrstAKRenzyme reported to display activitywith retinoids
was chicken AKR or AKR1B12 (Crosas et al., 2001). Since then,
a signiﬁcant amount of data has been reported on AKRs and
retinoids. In this review, this relevant topic will be discussed, as
AKRs are being established as enzymes that participate in the pre-
cise ﬁne tuning required for the ﬁrst and regulatory step of RA
biosynthesis. Regulation of this pathway by AKRs and its relation-
ship with retinoid body uptake and cell proliferation will also be
approached because of its pathological relevance.
CHARACTERIZATION OF AKRs AS RETINALDEHYDE
REDUCTASES
ACTIVITY ASSAY METHODOLOGIES AND KINETIC RESULTS FOR AKR
ENZYMES WITH RETINOIDS
In vitro kinetic studies on AKR enzymes with retinoids are fun-
damental to investigate isomer speciﬁcity, inhibitor selectivity,
and structure–function relationships. Retinoids are highly unsta-
ble hydrophobic compounds displaying very low solubility in
water-based solvents and being susceptible to photodegradation,
double-bond isomerization, and oxidation reactions. Thus, they
need to be handled under dim red light, and properly solubilized
and stabilized. In order to overcome these difﬁculties, two differ-
ent methodologies have been used to perform kinetic studies with
retinoids: (1) the ADH enzymatic assay (or Tween 80 assay), and
(2) the SDR enzymatic assay (or HPLC assay), both reviewed in
Parés et al. (2008).
The ADH enzymatic assay (or Tween 80 assay)
This assay is characterized by the use of an aqueous buffer con-
taining a low amount of the non-ionic detergent Tween 80 (poly-
oxyethylene (20) sorbitan monooleate) and the spectrophotomet-
ric measurement of the reaction at 25˚C, following retinaldehyde
absorbance at 400 nm, where retinol does not absorb. Table 1
lists the kcat values of the AKR1 enzymes obtained by using this
method. Km values are not included because Tween 80 behaves
as an apparently competitive inhibitor and thus, at the concentra-
tion used in the assay, there is a 10- to 100-fold increase of the
retinoid Km values (Martras et al., 2004; Ruiz et al., 2009). Some
of the values in Table 1 may not be fully comparable since kinetic
studies were performed in different laboratories using different
protein sources and methodologies, under various experimental
conditions. Thus, AKR1B12 results were obtained by using tissue-
puriﬁed instead of recombinant protein. Constants for AKR1B13,
1B14, 1B17, and 1C15 were measured with 0.01% (v/v) Tween
80 instead of the widely used 0.02% concentration. Other labora-
tories used a high concentration of organic solvent (e.g., 8%, v/v,
dimethylsulfoxide). Another added trouble with thismethodology
is its low reproducibility due to the high absorbance of retinalde-
hyde at 400 nm combined with the low activity rate shown by
AKR1 enzymes, resulting in high and variable background which
must be subtracted during activity assays. While this methodol-
ogy may still serve to perform routine determination of enzyme
activity, it is not useful for comparison of kinetic parameters with
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Table 1 | Catalytic constants (k cat, min−1) of AKR1 enzymes with
retinaldehyde isomers, obtained spectrophotometrically in the
presence ofTween 80.
Enzyme All-trans-retinaldehyde 9-cis-Retinaldehyde
1A2 N.A.a N.A.a
1B1 0.37b 2.84
1B10 17.8b 39.0c 5.20
1B3 11.6d N.D.
1B7 9.73d N.D.
1B8 15.3d N.D.
1B9 0.11 N.A.
1B12 17.0e 8.62e
1B13 N.A.f N.D.
1B14 N.A.g N.D.
1B17 0.58h N.D.
1C7* L.A.i N.D.
1C15 1.2j 2.8j
Activity was determined in 0.1M sodium phosphate, pH 7.5, 0.02% Tween
80, 0.2mM NADPH, at 25˚C. ND, not determined; NA, no activity was
detected or it was less than 0.5 nmolmin−1 mg−1. LA, low activity was detected,
4 nmolmin-1 mg-1. *Kinetics was performed in 0.1M potassium phosphate buffer,
pH 6.5, at 37˚C, and products were analyzed by reverse phase HPLC equilibrated
with 80% (v/v) acetonitrile in water. aCrosas et al. (2003), bGallego et al. (2007b),
cQuinn et al. (2008), dJoshi et al. (2010), eCrosas et al. (2001), fEndo et al. (2009),
gEndo et al. (2010a), hEndo et al. (2010b), iEndo et al. (2001), jEndo et al. (2007).
other enzymes, such as SDR, where activity has been typically
determined by using detergent-free buffer (Gough et al., 1998;
Parés et al., 2008).
The SDR enzymatic assay (or HPLC assay)
This assay uses an aqueous buffer containing retinoid/bovine
serum albumin at 1:1 molar ratio, reaction at 37˚C, followed by
retinoid extraction with hexane and analysis of the reaction prod-
ucts by HPLC. Determination of the reaction rate is based on
the percentage of substrate conversion. Compared to the Tween
80 assay, the HPLC assay is far more reproducible, it does not
alter the Km values, requires a lower amount of substrate and is
also suitable for cell culture experiments. Indeed, the compara-
tive activity analysis side-by-side of ADH, SDR, and AKRs with
retinoids revealed that all enzymes exhibited low and similar Km
values, 1μM or lower, while they differed in their kcat values.
Therefore, when possible, it is highly recommended to choose this
method instead of the Tween 80 assay.
Tables 2 and 3 show kinetic constants of AKR1 enzymes using
the HPLC assay. As it can be observed, Km values keep close to
1μM or lower, which is in the physiological range of retinol con-
centration (Hollander and Muralidhara, 1977; Quick and Ong,
1990; Harrison, 2012). In contrast, kcat values are clearly distinct
between different enzymes (Gallego et al., 2006; Ruiz et al., 2011b).
None of the rodent enzymes characterized displayed high kcat val-
ues, leaving human AKR1B10 and chicken AKR1B12 as the sole
potent all-trans-retinaldehyde reductases of the superfamily (Gal-
lego et al., 2006, 2007b; Ruiz et al., 2011a). On the other hand,
human AKR1C enzymes have been shown to use preferentially
Table 2 | Kinetic constants of AKR1 enzymes with retinaldehyde
isomers, obtained by the HPLC assay in the presence of BSA.
Enzyme All-trans-retinaldehyde 9-cis-Retinaldehyde
Km k cat k cat/Km Km k cat k cat/Km
1B1a 1.1 0.35 320 0.4 0.7 1500
1B3b 1.0 0.52 540 N.D.
1B7b 0.5 0.02 42 N.D.
1B8b 2.1 0.05 22 N.D.
1B9b 2.0 0.27 140 N.D.
1B10a 0.6 27 45000 0.7 0.9 1300
1B12 0.6 2.5 4100 N.D.
1C1c L.A. 0.48 0.18 370
1C2c N.A. N.A.
1C3c 1.4 0.60 430 0.40 13 32,500
1C4c 0.31 0.24 790 0.80 0.40 500
Activities were determined in 90mM KH2PO4, 40mM KCl, pH 7.4, 0.5mM
NADPH, 37˚C. NA, no activity; ND, not determined; LA, low activity was detected,
0.56 nmolmin−1 mg−1. Units: Km (μM), kcat (min−1), kcat/Km (mM−1 min−1). aGallego
et al. (2007b), bRuiz et al. (2011a), c Ruiz et al. (2011b).
Table 3 | Kinetic constants of AKR1 enzymes with retinol isomers,
obtained by the HPLC assay in the presence of BSA.
Enzyme All-trans-retinol 9-cis-Retinol
Km k cat k cat/Km Km k cat k cat/Km
1B10a 0.4 4.3 12300 N.A.
1B12 0.5 1.4 2900 N.A.
1C3b N.A. 0.30 0.26 850
Activities were determined in 90mM KH2PO4, 40mM KCl, pH 7.4, 2.3mM
NADP+, 37˚C. NA, no activity. Units: Km (μM), kcat (min−1), kcat/Km (mM−1 min−1).
aGallego et al. (2007b), bRuiz et al. (2011b).
9-cis-retinaldehyde, especially AKR1C3, which is unique in hav-
ing a high kcat value and a catalytic efﬁciency in the same order as
that of AKR1B10 with all-trans-retinaldehyde (Ruiz et al., 2011b).
Some AKR1B enzymes are also active toward ring-
oxidized retinoids, like all-trans-4-hydroxy, 4-oxo, and 3,4-
didehydroretinaldehyde (Ruiz et al., 2009). Reminiscent of what is
observed with ADH, kcat values increase between 4- and 20-fold
in AKRs with ring-oxidized retinoids in comparison with under-
ivatized retinoids (Martras et al., 2004; Ruiz et al., 2009). These
derivatives are involved in degradation pathways, but in some cases
they are bioactive compounds which can bind to nuclear recep-
tors. These results suggest that AKR1B enzymes may be potentially
involved in these pathways in vivo.
EFFECT OF CRBP-I AND MICROSOMAL MEMBRANES ON RETINOID
OXIDOREDUCTASE ACTIVITY
Cellular retinol binding protein type I is a cytosolic protein with
a widespread tissue distribution. Since CRBP-I binds retinol with
very high afﬁnity (K d for retinol ≈0.1 nM), retinol availability for
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enzymes in a cellular environment is an important issue. There-
fore, the activity of AKR1B10 with retinol, along with that of some
other oxidoreductases from the MDR and SDR superfamilies, was
checked in the presence of CRBP-I (Gallego et al., 2006) by using
theHPLC assay. The presence of CRBP-I seriously hampered enzy-
matic activity with retinol. All the enzymes analyzed could use
free retinol as a substrate but not retinol bound to CRBP-I. The
small activity found with holo-CRBP-I was attributed to the disso-
ciated free retinol which was in equilibrium with CRBP-I. This
point was conﬁrmed for microsomal RDH by other laborato-
ries (Belyaeva et al., 2005, 2008; Farjo et al., 2011) and suggests
that oxidoreductases may have limited access to retinol bound to
CRBP-I.
In addition, evidence indicates that a fraction of cellular retinol
is associated with membranes. In fact, retinol needs to be trans-
ferred to membranes of the endoplasmic reticulum in order to
be esteriﬁed by LRAT, and most SDR retinol dehydrogenases are
microsomal. Thus, the effect of added microsomal membranes on
the retinol dehydrogenase activity of AKR1B10 and representative
enzymes of two other oxidoreductase superfamilies was investi-
gated. Enzyme activity was inhibited in a dose-dependent manner
by microsomal membranes (Gallego et al., 2007a) and, in some
cases, by adding phospholipid-based liposomes (Farjo et al., 2011).
In conclusion, cytosolically located enzymes may not have access
to retinol bound to CRBP-I nor to that absorbed into membranes,
while microsomal enzymes could use the latter.
Retinaldehyde reductase activity of AKR1B1 and 1B10, side-by-
side with that of cytosolic ADH and microsomal SDR enzymes,
was also analyzed in the presence of CRBP-I (Gallego et al., 2006).
Although the enzymes examined only could use free retinalde-
hyde, they could still function in the presence of CRBP-I because
of a higher dissociation constant (K d for retinaldehyde ≈50 nM),
which results in a signiﬁcant fraction of free retinaldehyde found
in solution (Parés et al., 2008).
STRUCTURAL DETERMINANTS OF RETINALDEHYDE REDUCTASE
ACTIVITY IN AKRs
AKR1B1 is likely one of the best characterized proteins at struc-
tural level, with a large number of high quality structures solved
and some at unprecedented ultrahigh resolution (0.66 Å; Howard
et al., 2004). Many crystallographic structures of AKR1 ternary
complexes have been solved using enzyme inhibitors as ligands,
mostly because of their pharmacological relevance (Lovering et al.,
2004; El-Kabbani and Podjarny, 2007; Barski et al., 2008). In con-
trast, only one crystal structure of an AKR1B enzyme complex
with a substrate or analog has been obtained (AKR1B1–NADP-
glucose-6-phosphate, PDB 2ACQ) and only few for some AKR1C
enzymes. In this latter case, the studies were based on the use of
substrates showing low kcat values, which helped stabilizing the
ternary complex (i.e., AKR1C2–NADP-testosterone, PDB 1J96;
AKR1C3–NADP-prostaglandin D2, PDB 1RY0). As for retinoid
molecules bound to AKR enzymes, structural data are lacking
and only have been inferred from docking and molecular dynam-
ics (MD) simulations (Gallego et al., 2007b; Ruiz et al., 2009,
2011a,b). From these crystallographic and modeling studies, the
main interacting residues in the cofactor- and substrate-binding
sites could be identiﬁed. In the active site, the vast majority
of AKRs have a catalytic tetrad featuring Asp44, Tyr49, Lys78,
and His111 (AKR1B10 numbering). The most variable area in
the substrate-binding site between different enzymes is found in
loops A (residues 112–136), B (residues 212–226), and C (residues
297–307). Substrate speciﬁcity and inhibitor selectivity is mostly
determined by the interaction with residues located in these three
highly variable loops.
Members of subfamily AKR1A (aldehyde reductase) did not
show activity with retinoids. A larger loop C, with an insertion
of nine amino acid residues, not present in AKR1B and AKR1C
enzymes, could be the determinant for the absence of activity of
pig aldehyde reductase (AKR1A2) with retinoids, as it restricts the
access of bulky substrates and inhibitors to the cavity (Barski et al.,
1996; Crosas et al., 2003).
Regarding the subfamily 1B, as mentioned above, several
AKR1B1 inhibitor complexes have been obtained. In contrast, for
AKR1B10, only one three-dimensional structure, the ternary com-
plex AKR1B10–NADP+-tolrestat has been solved (PDB 1ZUA;
Gallego et al., 2007b). The comparison between AKR1B1 and
AKR1B10 structures allowed explaining the difference of 100
times in catalytic efﬁciency with all-trans-retinaldehyde. MD sim-
ulations showed that all-trans-retinaldehyde is a bulky mole-
cule which, in contrast to smaller molecules like tolrestat, inter-
acted through its cyclohexene ring with the outer region of the
substrate-binding pocket, especially with loops A and C. The most
remarkable amino acid substitutions in residues participating in
retinoid binding between AKR1B1 and AKR1B10 were observed
at positions 125 (Leu to Lys) and 304 (Cys to Ser).
Site-directed mutagenesis exchanging the AKR1B10 residues
for those of AKR1B1 (K125L and S304C) was performed and the
resulting single and double mutant enzymes were kinetically char-
acterized (Table 4). With all-trans-retinaldehyde, the kcat value of
both single mutants decreased more than 10 fold compared to the
wild-type enzyme,while the doublemutant showed a similar value
to that of the low-retinoid activity AKR1B1. The kinetics with dl-
glyceraldehyde was not affected by the substitutions likely because
these residues are located far from where small substrates bind.
Thus the kcat value for dl-glyceraldehyde was similar for all the
enzymes listed in Table 4, suggesting a common rate-limiting step,
likely cofactor dissociation. In contrast, large differences in the kcat
value with all-trans-retinaldehyde suggest that the rate-limiting
Table 4 | Catalytic constants (k cat, min−1) of AKR1B10, AKR1B10
K125L, and AKR1B10 S304C mutants, and AKR1B1.
Enzyme DL-Glyceraldehyde All-trans-retinaldehyde
AKR1B10 35 27
K125L 35.6 2.0
S304C 29 2.0
K125L/S304C 28 0.12
AKR1B1 31 0.35
Activities were determined in 0.1M sodium phosphate, pH 7.5, 0.2mM NADPH,
25˚C, with DL-glyceraldehyde, and in 90mM KH2PO4, 40mM KCl, pH 7.4, 0.5mM
NADPH, 37˚C, with all-trans-retinaldehyde, using the HPLC assay. Data from Ruiz
et al. (2011a).
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step for this substrate differs between AKR1B1 and AKRB10. It
is conceivable that either the chemical step or product release is
slower when retinaldehyde is the substrate in AKR1B enzymes,
the exception being AKR1B10, which has a similar kcat value
for all-trans-retinaldehyde and dl-glyceraldehyde.MDsimulation
and kinetics with ring-oxidized retinoids supported this notion,
although transient kinetic experiments would be required to con-
ﬁrm it unequivocally (Gallego et al., 2007b; Ruiz et al., 2009,
2011a).
Molecular dynamics simulations showed that binding of all-
trans-retinaldehyde to AKR1B10 required Lys125 to swivel toward
the solvent, something not required in the other models tested
(Figure 2; Gallego et al., 2007b). One interesting ﬁnding is that in
order to achieve a higher enzyme activity with retinoids, AKR1B
enzymes require a hydrophilic group to be present either in
the substrate cyclohexene ring or in enzyme residue 125, facil-
itating proper orientation of substrate for catalysis or product
release. When exchanging Ser304 by Cys in AKR1B10, some
FIGURE 2 | Models of all-trans-retinaldehyde docked into the AKR1B10
andAKR1B1 structures. (A)Tolrestat-binding pocket in the
AKR1B10–NADP+-tolrestat crystal. (B) All-trans-retinaldehyde binding
pocket of AKR1B10 predicted by our model. (C)Tolrestat-binding pocket in
the AKR1B1–NADP+-tolrestat crystal (PDB entry 2FZD). (D)
All-trans-retinaldehyde binding pocket of AKR1B1 predicted by docking and
MD.The molecular surface is colored according to the local electrostatic
potential as calculated with the program PYMOL (www.pymol.org).
Residues around the substrate deﬁne a highly hydrophobic and well
adjusted pocket, protecting the retinaldehyde molecule from the polar
solvent. Reproduced with permission from Gallego et al. (2007b).
Copyright©2007, National Academy of Sciences, USA.
hydrogen bonds and hydrophobic interactions between loops A
and C of AKR1B1 are predicted to be broken. Somehow, struc-
tural variations in the K125L/S304C double mutant may have
induced protein loop rearrangements and product–protein inter-
action changes (Ruiz et al., 2011a), which may explain the large
decrease in its kcat value, similar to that of the low-retinoid activ-
ity AKR1B1 (Table 4). Thus, Lys125 and Ser304, the latter being
unique to 1B10 and chicken 1B12 (also a highly active retinalde-
hyde reductase), are major structural determinants for all-trans-
retinaldehyde speciﬁcity of 1B10,as assessed by site-directedmuta-
genesis and molecular dynamics. In summary, retinoid speciﬁcity
in the 1B subfamily seems to be governed by hydrophilic contacts
in the outer part of the substrate-binding site and by loop–loop
interactions.
As described above, human 1C subfamily members, espe-
cially AKR1C3, are predominantly 9-cis-retinaldehyde reductases.
AKR1C enzymes have some amino acid insertions at their N-
terminal region and also a shorter loop B in the part interacting
with the cofactor. This smaller loop makes the chemical step and
product release to be more rate-limiting than cofactor dissocia-
tion in comparison to 1A and 1B enzymes (Jin and Penning, 2006;
Barski et al., 2008). Binding of retinaldehyde isomers to AKR1C1,
a low activity enzyme, and AKR1C3, a high activity enzyme, was
compared and the computer models obtained were very similar
in their overall structure, but with some subtle changes. Trp227,
located in loop B and conserved in the two proteins, adopted
different conformations in the complexes, resulting in different
loop arrangements. Structural analysis suggested that the vari-
ation in the conformation could be due to residue 226, Arg in
AKR1C3, and Pro in AKR1C1, resulting in a more rigid and
tighter loop B. The importance of this residue was partially sup-
ported by a moderate drop in the catalytic efﬁciency of AKR1C3
R226P and R226Q mutants. Additional structural features might
contribute to the kcat difference between the two enzymes. Prob-
ably, the wider and more hydrophilic site of AKR1C3 could
facilitate binding of 9-cis-retinaldehyde. The lower activity of
AKR1C3 with all-trans-retinaldehyde could also be explained by
a distinct loop B conformation in the complex with this iso-
mer, whose different geometry resulted in a positioning similar
to that of the AKR1C1:9-cis-retinaldehyde complex (Ruiz et al.,
2011b).
BIOLOGICAL ROLE OF AKRs AS RETINALDEHYDE
REDUCTASES
RETINALDEHYDE REDUCTASE ACTIVITY OF AKRs IN CELLULAR MODELS
Since AKR enzymes had been characterized in vitro as retinalde-
hyde reductases, their activity was also tested in different cellular
models, namely, primary cell cultures as well as tumor cell lines.
In order to identify endogenous or transfected AKRs as the ori-
gin of retinaldehyde reductase activity, two different experimental
approaches were used, i.e., enzyme overexpression and/or the use
of enzyme inhibitors.
Primary cultures of human aortic smooth muscle cells, when
stimulated to proliferate, overexpressed AKR1B1 and converted
35% of added retinaldehyde to retinol. This conversion decreased
by 40% when cells were incubated in the presence of tolrestat, an
AKR1B1 inhibitor. Therefore, AKR1B1, which typically shows low
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in vitro enzyme activity, acted as a retinaldehyde reductase in a
cellular environment, which points out to a signiﬁcant role in vivo
(Gallego et al., 2006).
Monkey kidney COS-1 cells, when transiently expressing
AKR1B10, doubled their capacity for all-trans-retinaldehyde
reduction (Gallego et al., 2007b). Overexpression of AKR1B10
in human airway epithelial 16HBE cells treated with retinalde-
hyde also increased retinol production (Wang et al., 2010). Lastly,
human lung adenocarcinoma A549 cells showed a retinaldehyde
reducing activity of 9.6± 0.8 nmolmin−1 mg−1, which was inhib-
ited by 50% upon treatment with ponalrestat (an AKR1B1 and
AKR1B10 inhibitor; Quinn et al., 2008).
Breast adenocarcinoma MCF-7 cells were used as a model to
study retinaldehyde reductase activity of AKR1C enzymes. These
cells exhibit very low retinol oxidation activity, down-regulated
retinol esteriﬁcation and low retinaldehyde oxidation. Retinalde-
hyde reduction was found to be very high and approximately
30% of this activity was due to AKR1C enzymes, presumably to
AKR1C3, as shown by ﬂufenamic acid inhibition (an AKR1C1
and AKR1C3 inhibitor). The reductive metabolism of 9-cis-
retinaldehyde was less signiﬁcant, althoughAKR1C3 andAKR1C1
were responsible for approximately 90%of this activity (Ruiz et al.,
2011b).
As for the oxidizing activity, transfection in COS-1 cells with
AKR1B10 did not increase conversion of externally added retinol
to retinaldehyde (Gallego et al., 2007b) and AKR1C3 inhibition
had no effect on the retinol conversion in MCF-7 cells (Ruiz et al.,
2011b). Thus, both AKR1B and AKR1C enzymes could not func-
tion as retinol dehydrogenases in cell culture. These results were
expected since, in metabolically active cells,NADP is mostly found
in its reduced state and therefore reductive metabolism by NADP-
dependent enzymes is favored over oxidative reactions (Barski
et al., 2008). A similar ﬁnding had been previously described in
COS-1 cells,where transient transfection of AKR1C enzymes indi-
cated that they function as ketosteroid reductases (Penning et al.,
2004).
Overall, these studies using different cellular models conﬁrm
that the retinaldehyde reductase activity of humanAKRs may have
an in vivo role in the RA biosynthetic pathway.
EFFECT OF AKR ACTIVITY ON RA SIGNALING THROUGH PRE-RECEPTOR
REGULATION
Having demonstrated that AKRs are able to decrease in vitro and
cellular retinaldehyde levels, we explored whether their retinalde-
hyde reductase activity might also deplete RA levels thus affecting
RA signaling. For this purpose,HeLa cells were transiently cotrans-
fected with an AKR expression plasmid and a RARE reporter
plasmid, and treated with either all-trans or 9-cis-retinol. Over-
expression of each of AKR1B1, 1B10, 1C3, and 1C4 decreased
both all-trans- and 9-cis-RA-dependent trans-activation,meaning
a lower amount of RA being produced due to their retinaldehyde
reductase activity (Ruiz et al., 2009, 2011b). This result implies that
AKR1B and 1C enzymes are part of a ﬁne tuning regulating system
of RA biosynthesis, carried out by proteins from different super-
families, such asAKR,MDR, and SDR, and described earlier in this
review. Overall this indicates that AKR enzymes may contribute
to pre-receptor down-regulation of RAR and RXR transcriptional
activity,which could lead to cell proliferation and increased cancer
risk in target tissues.
It is well known that these enzymes and other members of
the human AKR1A, 1B, and 1D subfamilies are able to use as
substrates lipophilic molecules other than retinoids, including
steroids, prostaglandins, and polycyclic aromatic hydrocarbons.
Interestingly, these compounds or their derivatives act as ligands of
a wide variety of nuclear hormone receptors (Penning and Drury,
2007),which suggests a biological function in the regulation at pre-
receptor level. Consequently, the retinaldehyde reductase activity
of AKR1B and 1C enzymes can now be added to this complex
regulatory interplay.
ROLE OF AKR1C3 IN THE CONTROL OF 9-cis-RA LEVELS
The 9-cis isomer of RA binds to both RAR and RXR with high
afﬁnity in vitro, and has diverse pharmacological actions which are
distinct from those of all-trans-RA. Intensive analytical research in
quantifying RA isomers had not detected 9-cis-RA in serum and in
a variety of tissues, until the recent identiﬁcation of this isomer in
pancreas, where it plays a role in regulation of glucose-stimulated
insulin secretion (Kane et al., 2010; Kane, 2012). About 80% of
pancreatic 9-cis-RA is concentrated in β-cells, which represent less
than 5% of the total pancreatic cell population. This indicates a
very discrete cellular localization of this isomer. It is possible that
9-cis-RA may only be present in a local cell population in other
tissues, and thus dilution of the isomer in the homogenate of
the whole tissue may preclude its detection. A source of 9-cis-RA
could be 9-cis-retinol, which has been detected in pancreas and
other tissues (Kane, 2012), while enzymes oxidizing 9-cis-retinol
and 9-cis-retinaldehyde are widespread (Table 5). In addition, 9-
cis carotenoids found in the diet can produce 9-cis-retinaldehyde
by the action of BCO1 (Kane, 2012). Levels of 9-cis-retinaldehyde
would be controlled by the action of oxidoreductases. In general
retinaldehyde oxidoreductases are more speciﬁc for the all-trans
than for the 9-cis isomer (Table 5), except for severalAKRenzymes,
especially AKR1C3. The robust AKR1C3 activity with the 9-cis
form is comparable or higher than that of the members of other
enzyme superfamilies, supporting a role in the control of 9-cis-RA
signaling. Speciﬁcity for the 9-cis over the all-trans isomer has also
been observed in other enzymes, such as RDH5 (Mertz et al., 1997)
and ALDH8A1 (Lin and Napoli, 2000).
ROLE OF CYTOSOLIC AKRs IN SUBCELLULAR RETINALDEHYDE
METABOLISM
As discussed above, in vitro and cellular studies indicate that AKRs
could be involved in the reduction of retinaldehyde to retinol. Fur-
thermore, this activity could modulate RA synthesis, conﬁrming
that the control of retinaldehyde levels is essential in the regulation
of RA function.
Available evidence supports cellular compartmentalization of
retinoid metabolism. The enzymes involved in RA synthesis are
localized in different subcellular compartments. In addition, the
low solubility of retinol and retinaldehyde in water also inﬂuences
their distribution in the cell. In the cytoplasm, retinol is tightly
bound to CRBP-I (Napoli, 1999). Retinol is also found in free
form incorporated into endoplasmic reticulummembranes,which
is supported by the observation that CRBP-I can transfer retinol
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Table 5 | Properties of human retinaldehyde oxidoreductases with reported kinetic constants.
Enzyme Substrate Reaction
(cofactor)
Subcellular
localization
Tissue distribution Reference
All-trans-Ral 9-cis-Ral
k cat/Km Vmax/Km k cat/Km Vmax/Km
AKR1B1 320 8.3 1500 45
Reduction
(NADPH)
Cytosolic
Widespread Gallego et al. (2007b),
Grimshaw and Mathur (1989)
AKR1B10 45000 1200 1300 33 Small intestine, adrenal
gland, colon liver,
thymus
Gallego et al. (2007b),
Hyndman and Flynn (1998),
Cao et al. (1998)
AKR1C1 L.A. 370 10 Lung, liver testis,
mammary gland
Ruiz et al. (2011b), Penning
et al. (2000)
AKR1C3 430 11 32,500 850 Mammary gland,
prostate liver, lung
Ruiz et al. (2011b), Penning
et al. (2000)
AKR1C4 790 20 500 13 Liver Ruiz et al. (2011b), Penning
et al. (2000)
RDH11 N.D. 4200 N.D. 8.4*
Reduction
(NADPH)
Microsomal
Widespread Belyaeva et al. (2003),
Kedishvili et al. (2002)
RDH12 900000 25000 100000 2800 Retina> kidney>
pancreasother
Belyaeva et al. (2005)
RDH14 N.D. 340* N.D. Widespread Belyaeva and Kedishvili (2002)
ALDH1A1 N.D. 3700, 4.2** N.D. 5.6**
Oxidation
(NAD+)
Cytosolic
Widespread Yoshida et al. (1992), Xi and
Yang (2008), King and Holmes
(1998), Gagnon et al. (2002)
ALDH1A2 N.D. 6.5
†
N.D. 1.2
†
Testis, ovary>pancreas,
placenta lung,
intestine, liver
Xi andYang (2008), Gagnon
et al. (2002)
ALDH1A3 1170000 5000 N.D. Widespread Xi andYang (2008), Graham
et al. (2006)
ALDH8A1 L.A.# N.D. 0.23# Kidney and liver Lin and Napoli (2000)
All activities were measured using puriﬁed enzymes unless indicated otherwise. kcat/Km, min−1 mM−1; Vmax/Km, nmolmin−1 mg−1 μM−1; kcat values of AKRs were cal-
culated using Mr=38500; Values with puriﬁed SDR enzymes were taken from Parés et al. (2008); ND, not determined; LA, low activity; Ral, retinaldehyde; *Kinetic
constants using microsomal fractions of transiently transfected cells; **Kinetics were performed with the presence of Tween 80 in the activity buffer; † Kinetic
constants of mouse enzyme; #Kinetic constants using whole cell lysates of transiently transfected cells.
to phospholipid membranes (Herr et al., 1999). LRAT and REH
are both membrane-bound enzymes and LRAT-enriched micro-
somal fraction uses efﬁciently retinol bound to membranes or to
CRBP-I (Ghyselinck et al., 1999; Gallego et al., 2006). As we have
previously seen, the human enzymes involved in the redox trans-
formations of retinol and retinaldehyde are not active with the
CRBP-I-retinol complex, but only with free retinol (Gallego et al.,
2006; Farjo et al., 2011). In fact, CRBP-I is not needed for retinol
oxidation since mice lacking CRBP-I did not exhibit decreased RA
synthesis but instead they had greatly reduced their stores of liver
retinyl esters (Ghyselinck et al., 1999). Interestingly, double trans-
genic mice lacking CRBP-I and ADH recovered normal levels of
retinyl esters,meaning that CRBP-Imight protect free retinol from
being oxidized to retinaldehyde and converted to RA. Interestingly,
mouse loss-of-function models indicate that the highly active
cytosolic ADH show a minor role in RA synthesis during embry-
onic development, while the less active microsomal RDH10 (an
SDRmember,also inactivewithCRBP-I-bound retinol) is essential
(Farjo et al., 2011; Kumar et al., 2012). This suggests that RDH10,
but not ADH, has access to free retinol absorbed into the mem-
brane, and that the physiological oxidation of retinol occurs pre-
dominantly in a membrane-bound cellular compartment (Farjo
et al., 2011).
As opposed to retinol, retinaldehyde metabolism has distinct
localization features. As we have discussed previously, CRBP-I
binds less tightly retinaldehyde (Gallego et al., 2006; Kane et al.,
2011), which can be more easily released to its free form than
retinol in the cytoplasm. A physiological implication of this fact is
that the presence of CRBP-I appears to favor retinaldehyde metab-
olism over that of retinol oxidation in the cytosol. Oxidation to
RA is a cytosolic step since the four ALDH involved (1A1, 1A2,
1A3, and 8A1) are soluble proteins. Interestingly, although addi-
tionalALDHare localized in other subcellular compartments (e.g.,
endoplasmic reticulum, mitochondria, or peroxisomes), they are
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not active with retinaldehyde. In contrast, retinaldehyde reduction
could be catalyzed either by microsomal SDR or by the cytosolic
AKRs. The contribution of each enzyme, and the direction (oxi-
dation or reduction) of the reaction, will depend on its amount in
a speciﬁc tissue in a precise moment during fetal development or
adult life, and on its kinetic properties. Table 5 lists the kinetic
and localization properties of major enzymes of retinaldehyde
redox transformations. Although comparison of kinetic constants
should be done with caution because of different methodologies
used, it is apparent that SDR and ALDH are the most efﬁcient
enzymes. Using knockout animals, it has been well demonstrated
that the three most active ALDH involved are essential for nor-
mal embryonic development of mice (Farjo et al., 2011; Kumar
et al., 2012). It is also clear that AKR1B10 and AKR1C3 exhibit
remarkable efﬁciencies, comparable to those of enzymes from the
other superfamilies. Thus, in tissues with increased expression,
either normal tissues or in the pathological conditions discussed
below, participation of AKR1B10 and AKR1C3 in the control of
retinaldehyde levels could be relevant, which would directly affect
the RA signaling pathway.
In summary, collected data situates the ﬁrst step of RA biosyn-
thesis (retinol to retinaldehyde) mainly in the membrane of
endoplasmic reticulum, while the second step (retinaldehyde oxi-
dation) is cytosolic. Finally, retinaldehyde reduction, which reg-
ulates the ﬂow of RA synthesis, can happen in either subcellular
compartment, with the likely contribution of cytosolic AKRs.
PUTATIVE FUNCTION OF AKRs IN THE METABOLISM OF DIETARY
PROVITAMIN A CAROTENOIDS
Dietary carotenoids are a major source of vitamin A metabolites.
In humans, about one half of absorbed β-carotene is cleaved in
the intestinal mucosa by BCO1 to yield two molecules of reti-
naldehyde. This is then reduced to retinol by poorly characterized
reductases, esteriﬁed, and the resulting retinyl ester incorporated
into chylomicrons. Intact carotenoids can be directly incorporated
into chylomicrons and delivered to the liver, and in association
with lipoproteins can be also takenupby extrahepatic tissues (Har-
rison, 2012; Lobo et al., 2012). BCO1 is abundant in intestine and
liver, but it is also expressed in a variety of tissues in the embryo
and adult, suggesting that local speciﬁc conversion of β-carotene
may contribute to retinoid metabolism in peripheral tissues (Lobo
et al., 2012). AKR1B10 and otherAKRs are also present in intestine
and in several tissues (Table 5), and could have a role in the reduc-
tion of retinaldehyde produced by the BCO1 action. Furthermore,
the cytosolic localization of the BCO1 catalyzed reactionmay favor
the participation of either AKRs or ALDH in the metabolic fate of
retinaldehyde.
ROLE OF RETINALDEHYDE REDUCTASE ACTIVITY OF AKRs IN
PROLIFERATION AND TUMORIGENESIS
Upregulation of some AKR1 enzymes in different types of cancer
has been widely reported (reviewed in Ruiz et al., 2009, 2011b).
AKR1B10 was initially identiﬁed as a protein expressed in hepa-
tocellular carcinoma and its mRNA was also found elevated in
a number of cancer cell lines, especially in non-small cell lung
cancer and adenocarcinoma (Zeindl-Eberhart et al., 2004; Fuku-
moto et al., 2005). AKR1B1 has been shown to be involved in colon
carcinomas (Tammali et al., 2006).AKR1C3was overexpressed in a
wide variety of tumors, including breast and prostate cancer, either
in an hormone-dependent or independent manner (Penning and
Byrns, 2009) and leukemia (Desmond et al., 2003).
Generally, the induction of AKR1 enzymes could be explained
as a part of the cellular defense response against oxidative stress
(Jin and Penning, 2007). Tobacco components and other xenobi-
otics generate reactive oxygen specieswhich induceAKR1 enzymes
in their role as phase I drug-metabolizing enzymes (Figure 3).
Indeed, AKR1B1, AKR1B10, and AKR1C1–AKR1C3 belong to the
battery of genes regulated by antioxidant response elements via
the Nrf2–Keap-1 complex in humans (Jin and Penning, 2007;
Penning and Lerman, 2008; MacLeod et al., 2009; Ebert et al.,
2011). AKR1 enzymes, in some cases, contribute to chemother-
apeutic drug resistance, which could be rationalized by a direct
action through enzymatic activity in the case of carbonyl-bearing
compounds, i.e., daunorubicin (Novotna et al., 2008; Verma et al.,
2008; Zhong et al., 2011), or indirectly, by reducing oxidative stress
generated by these agents (Deng et al., 2004). Consequently,AKR1
enzyme inhibitors could be useful since they would be able to
enhance the therapeutic efﬁcacy of anticancer drugs by prevent-
ing chemoresistance (Jin and Penning, 2007; Martin and Maser,
2009; Wang et al., 2009; Shen et al., 2011).
A putative mechanism by which the activity of AKR1 enzymes
could promote tumor growth is the conversion of retinaldehyde
to retinol which would provoke RA deprivation and blockage of
its differentiating effect, promoting cell proliferation, and foster-
ing tumorigenesis (Figure 3). According to the model for retinoid
pre-receptor metabolism and regulation in target tissues, CRBP-I
acts favoring retinol storage into membranes and because of its
high afﬁnity for retinol and low one for retinaldehyde restricts
the availability of the ﬁrst and allows retinaldehyde reductases to
display their activity (Parés et al., 2008). Overexpression of AKR1
enzymes found in some cancers would favor retinaldehyde reduc-
tion (Penning, 2005). In fact, lung adenocarcinoma cell line A549
possesses a robust retinaldehyde reductase activity, due mostly
to AKR1B10 (and to AKR1B1 to a lesser extent; Quinn et al.,
2008).
Regarding AKR1B10, due to its high catalytic efﬁciency with
all-trans-retinaldehyde, the importance of the RA-related effect
on tumorigenesis is a strong possibility. RA is a crucial factor in
airway epithelial differentiation and its local deﬁciency could pro-
mote carcinogenesis of the airway epithelium. Upregulation of
AKR1B10 may be an early event in carcinogenesis, as its expres-
sion is elevated in squamous metaplasia and precancerous lesions
of non-small cell lung carcinoma. This is why it has been suggested
as an early detection marker and treatment target for non-small
cell lung carcinoma (Fukumoto et al., 2005). Also, AKR1B10 is a
smoking-responsive gene, and its upregulation is not limited to
squamous metaplasia and cancer tissues but occurs in the airway
epithelium in response to smoking (even healthy smokers show
induction of AKR1B10 expression). AKR1B10 high activity would
also explain the failure of β-carotene supplementation to reduce
lung cancer risk, because AKR1B10 would prevent RA generation
(Penning, 2005; Quinn et al., 2008).
AKR1C3 induction is related tohormone-dependent breast and
prostate cancer and now with a putative relevant role in cancer
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FIGURE 3 | Relationship of AKR1 enzymes with carcinogenesis at
different levels. Firstly, reactive oxygen species (ROS), such as these
generated by tobacco smoke, trigger the expression of some AKR1
enzymes (steps 1, 2, 3). Subsequently, activity of AKR1 enzymes with
retinaldehyde provokes retinoic acid (RA) deprivation blocking its
differentiating effect (steps 4′ and 5′), and favoring cell proliferation.
Besides, AKR1 enzymes participate in the detoxiﬁcation of lipid
peroxidation aldehydes and can also metabolize various antitumoral
agents bearing a carbonyl group (step 4). Through these activities, the
enzymes promote cell survival and chemotherapeutic drug resistance
(step 5). Overall, induction of AKR1 enzymes foster tumorigenesis (steps
6 and 6′).
related to RA signaling. Recently, cell proliferation was studied in
human promyelocytic leukemia HL-60 cells, which endogenously
express AKR1C3 (Ruiz et al., 2011b). It was demonstrated that the
pro-proliferative action of AKR1C3 was mediated in part by the
RA signaling pathway. Speciﬁcally, the addition of lithocholic acid
(an AKR1C3 inhibitor) enhanced the antiproliferative effect of 9-
cis-retinol. The inhibition of AKR1C3 could cause an increased
ﬂow in the synthesis of 9-cis-RA and, consequently, a lower pro-
liferation rate. The fact that HL-60 cells possess the enzymatic
machinery to produce RA, as well as RAR and RXR, makes plausi-
ble that the observed effect was due to the action of 9-cis-RA. The
use of an RAR antagonist restored the proliferation levels obtained
with 9-cis-retinol alone, conﬁrming that the observed effects were
mediated via the RA signaling pathway.
Desmond et al. (2003), by using the same HL-60 model, had
previously shown that AKR1C3 inhibition caused cell differentia-
tion and increased synthesis of 15-deoxy-Δ12,14-prostaglandin J2
(15Δ-PGJ2), a PPARγ ligand. Taken together these results indi-
cate that induced AKR1C3 activity may deplete the agonists of
both PPARγ and RAR, resulting in cell proliferation and tumor
progression. Therefore, an intriguing possibility arises: AKR1C3
may regulate antiproliferative signalingmediatedbyheterodimeric
complexes between PPARγ and RXR and thus enzyme inhibitors
could increase the 9-cis-retinol/RA antiproliferative effect, with
a potential use in leukemia treatment (Figure 4; Ruiz et al.,
2011b).
FIGURE 4 | Putative effect of AKR1C3 inhibition in HL-60 cells. A model
for AKR1C3 role in leukemia is shown: AKR1C3 inhibition leads to an
increase of the 9-cis-RA synthesis ﬂow, favoring ligand binding to RAR and
RXR. In addition, AKR1C3 inhibition causes an increased synthesis of
15-deoxy-Δ12,14-prostaglandin J2 (15Δ-PGJ2), which is the ligand for PPARγ.
Activated RXR and PPARγ form heterodimeric complexes and bind to gene
regulatory elements. Thus, AKR1C3 inhibition promotes differentiation
through these two signaling pathways, inhibiting tumor progression.
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In conclusion, accumulated experimental evidence with AKRs
and retinoids adds further support to the previous notion that
enzymatic activity of AKRs plays a role in the hormonal regulation
of cell proliferation at pre-receptor level. In addition, the
AKR-mediated modulation of RXR and their ability to form het-
erodimeric complexes with other nuclear receptors raises the pos-
sibility of cross-talk between different signaling pathways. Unbal-
ancedAKR expression may lead to dedifferentiation and increased
cancer risk in target tissues, and provides a rationale for the design
of AKR inhibitor-based drugs. The structural determinants, here
reported, of the unique retinaldehyde speciﬁcity of AKR1B10 and
1C3, the most relevant AKRs in cancer generation, may facilitate
the ﬁnding of selective inhibitors with therapeutic interest.
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